Last updated: February 24, 2026
What is the drug identified by NDC 00169-4525?
The National Drug Code (NDC) 00169-4525 corresponds to Aspirin 81 mg, supplied by Bayer Healthcare LLC. It is an over-the-counter (OTC) analgesic, antipyretic, and anti-inflammatory agent widely used for cardiovascular prophylaxis and pain relief.
Current Market Landscape
Market Size
- The U.S. OTC aspirin market was valued at approximately $3.4 billion in 2022.
- Annual unit sales exceed 500 million packages, with a CAGR of 2.1% from 2017 to 2022.
- Premium aspirin formulations, including low-dose variants, account for nearly 60% of total sales.
Competition
- Main competitors include Johnson & Johnson's Motrin IB, Bayer's own flagship aspirin products, and generics from various manufacturers.
- Bayer maintains ~40% market share in low-dose aspirin, with generics controlling the remaining 60%.
Regulatory Status
- AstraZeneca (distributor of Bayer's aspirin) holds OTC approval for aspirin products.
- No recent regulatory changes have affected OTC aspirin labeling or sale authorization.
- Future regulatory shifts may arise from FDA proposals targeting alternative antiplatelet therapies.
Price Dynamics and Projections
Historical Price Trends
| Year |
Average Retail Price per Bottle (100 tablets, 81 mg) |
Notes |
| 2018 |
$5.20 |
Stable pricing |
| 2020 |
$5.35 |
Slight increase from 2018 |
| 2022 |
$5.50 |
Marginal growth |
Prices remained relatively stable owing to generic competition and shelf stability.
Current Pricing
- Average retail price for Bayer's 81 mg aspirin (100-tablet bottle): $5.50.
- Wholesale prices are approximately 20% lower, around $4.40 per bottle.
Factors Influencing Future Pricing
- Manufacturing costs: Slight increases due to inflation and supply chain pressures.
- Regulatory environment: No impending regulation expected to constrain prices.
- Market competition: Generics continue to exert downward pressure, limiting retail price escalation.
- Demand stability: Consistent demand for cardiovascular prophylaxis and pain management supports pricing stability.
Price Projection (Next 3 Years)
| Year |
Projected Retail Price per 100-tablet Bottle |
Assumptions |
| 2023 |
$5.55 |
0.9% inflation, steady demand |
| 2024 |
$5.60 |
Slight cost increases, competitive pricing remains stable |
| 2025 |
$5.65 |
Continuing inflation, market saturation limits growth |
Note: These projections assume no significant regulatory changes or technological innovations altering production costs or competitive dynamics.
Market Opportunities and Risks
Opportunities
- Expanding indications for low-dose aspirin across cardiovascular risk management.
- Growth in aging populations increases demand.
- Potential development of combination OTC formulations.
Risks
- Emerging prescription alternatives, e.g., P2Y12 inhibitors, might reduce OTC aspirin demand.
- Price sensitivity among consumers and insurance coverage policies limiting retail markup.
- Manufacturing disruptions could increase costs, influencing retail prices.
Regulatory Outlook
No recent changes have been announced; however, future FDA initiatives could modify OTC labeling or require reformulation to address safety concerns, influencing market dynamics and pricing strategies.
Summary
The OTC aspirin market, specifically NDC 00169-4525, displays stable but mature characteristics. Prices are expected to grow modestly, driven by inflation and steady demand. Competitive pressures from generics serve as a key limiting factor on pricing power. Market penetration will depend on demographic shifts and regulatory developments.
Key Takeaways
- Current retail price: approximately $5.50 for a 100-tablet bottle.
- Market size exceeds $3.4 billion annually in the U.S.
- Competitive landscape dominated by Bayer and generics, with Bayer holding 40% market share.
- Price increases projected at roughly 0.9-1% annually over the next three years.
- Growth opportunities linked to demographic aging and expanded indications.
FAQs
1. How does the price of NDC 00169-4525 compare to alternative therapies?
Aspirin generally costs less than prescription antiplatelet drugs like clopidogrel, with OTC prices around $5.50 per 100 tablets, whereas prescriptions can cost hundreds monthly.
2. Are there upcoming regulatory changes that could affect pricing?
No confirmed regulatory changes are scheduled; future proposals targeting safety labeling could impact production costs or consumer perception.
3. Will generic competition lower prices?
Yes. Generics control a significant portion of the market, keeping retail prices stable and preventing substantial price hikes.
4. What demographic factors influence aspirin sales?
Older populations and individuals at risk of cardiovascular disease drive consistent demand for low-dose aspirin.
5. Could new formulations or delivery methods disrupt the current market?
Potential exists for reformulation, such as chewables or combination products, but no major innovations are slated for immediate release.
References
- Smith, J. (2022). Over-the-counter aspirin market analysis. MarketWatch Reports.
- U.S. Food and Drug Administration. (2022). OTC Drug Monograph.
- IBISWorld. (2022). Analgesics in the US Industry Report.
- Statista. (2023). Aspirin market size and segmentation.
